SCHEMBL4170079

SCHEMBL4170079

CCOC(=O)c1[nH]c2c(Br)cccc2c1CCCOc1cc(C)cc(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 13/20 0.56
HTR6 P50406 2/20 0.45
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
HTR1F P30939 1/20 0.45
HTR7 P34969 1/20 0.45
DRD3 P35462 1/20 0.45
CDC7 O00311 1/20 0.44
MARK3 P27448 1/20 0.44
AXL P30530 1/20 0.44
FRK P42685 1/20 0.44
BLK P51451 1/20 0.44
NEK4 P51957 1/20 0.44
PRKCD Q05655 1/20 0.44
MAP4K2 Q12851 1/20 0.44
CAMK2B Q13554 1/20 0.44
CAMK2G Q13555 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166001 0.94 MCL1 (0.53) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL15622097 0.89 MCL1 (0.71) MCL1BCL2
SCHEMBL4168089 0.88 MCL1 (0.57) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4174789 0.86 MCL1 (0.58) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4166844 0.86 MARK3 (0.62) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4158883 0.85 MCL1 (0.50) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4162321 0.85 MCL1 (0.49) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4170647 0.85 MCL1 (0.49) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4175362 0.83 HTR6 (0.51) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL19615316 0.83 HTR6 (0.51) MCL1HTR6HTR1ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3243814-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 EP disclosed
US-9359296-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2016-06-07 US disclosed
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC (US) 2015-10-08 US disclosed
US-9035047-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2015-05-19 US disclosed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 US disclosed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 US disclosed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP disclosed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885HTR6 1316/4885HTR1A 1631/4885
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885HTR6 1316/4885HTR1A 1631/4885
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885HTR6 1316/4885HTR1A 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.